Pharmaceutical

CRISPR-based assay could revolutionise diagnosis of NTM infections

The CRISPR-based assay significantly accelerates the current diagnostic process, which can last for months and could revolutionise the way NTM infections are diagnosed.

Mar 26, 2024 - 00:00
CRISPR-based assay could revolutionise diagnosis of NTM infections
The CRISPR-based assay significantly accelerates the current diagnostic process, which can last for months and could revolutionise the way NTM infections are diagnosed.
Read the original article

Tags:

Previous Article

Elahere secures full approval from FDA for types of ovarian cancer

Next Article

Esperion snags US label expansion for cardiovascular disease drugs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Drugs are still mostly tested in white men. Will the FDA change that next year?

STAT+: Drugs are still mostly tested in white men. Will...

Dec 21, 2023

STAT+: ‘I never realized what people go through’: Doctor and former hospital CEO with Stage 4 cancer calls for greater empathy in medicine

STAT+: ‘I never realized what people go through’: Docto...

Nov 15, 2023

Bristol Myers Squibb’s Reblozyl reinforces market share in first-line MDS Space

Bristol Myers Squibb’s Reblozyl reinforces market share...

Sep 13, 2023